Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0811 SAD Study in Healthy Chinese Adults
NCT07345364Phase 1Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SIM0811 with Placebo (2 arms). Primary endpoint: Adverse Events. Started Jan 2026; status: completed.
02
Drugs
SIM0811
Beyond the preview
Go deeper on NCT07345364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07345364.